Scott Auerbach
Concepts (387)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 40 | 2025 | 709 | 7.740 |
Why?
| | Heart-Assist Devices | 20 | 2025 | 557 | 3.690 |
Why?
| | Heart Failure | 25 | 2025 | 2067 | 2.780 |
Why?
| | Graft Rejection | 13 | 2025 | 536 | 2.190 |
Why?
| | Graft Survival | 11 | 2025 | 491 | 2.070 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2025 | 85 | 1.160 |
Why?
| | Heart Defects, Congenital | 11 | 2025 | 863 | 1.150 |
Why?
| | Cardiomyopathies | 10 | 2025 | 325 | 1.120 |
Why?
| | Child | 56 | 2025 | 21921 | 1.070 |
Why?
| | Transcriptome | 11 | 2025 | 967 | 1.030 |
Why?
| | Heart Diseases | 3 | 2023 | 335 | 1.030 |
Why?
| | Gene Expression Profiling | 9 | 2025 | 1746 | 1.030 |
Why?
| | Liver | 8 | 2024 | 1805 | 1.010 |
Why?
| | Toxicity Tests | 6 | 2025 | 40 | 0.970 |
Why?
| | Toxicogenetics | 5 | 2023 | 6 | 0.880 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 741 | 0.830 |
Why?
| | Steroids | 2 | 2015 | 163 | 0.820 |
Why?
| | Myocarditis | 2 | 2023 | 100 | 0.790 |
Why?
| | Carcinogens | 4 | 2022 | 126 | 0.790 |
Why?
| | Child, Preschool | 26 | 2025 | 11158 | 0.750 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 622 | 0.720 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 849 | 0.690 |
Why?
| | Registries | 15 | 2025 | 2073 | 0.680 |
Why?
| | Toxicology | 4 | 2025 | 44 | 0.680 |
Why?
| | Kidney Transplantation | 2 | 2023 | 655 | 0.670 |
Why?
| | Adolescent | 36 | 2025 | 21564 | 0.650 |
Why?
| | Environmental Pollutants | 4 | 2025 | 160 | 0.640 |
Why?
| | Organ Transplantation | 4 | 2024 | 241 | 0.630 |
Why?
| | Small Molecule Libraries | 2 | 2017 | 94 | 0.610 |
Why?
| | Humans | 93 | 2025 | 138651 | 0.610 |
Why?
| | Liver Neoplasms, Experimental | 2 | 2018 | 26 | 0.610 |
Why?
| | Mutagens | 4 | 2019 | 23 | 0.580 |
Why?
| | Retrospective Studies | 23 | 2025 | 15909 | 0.550 |
Why?
| | Treatment Outcome | 19 | 2025 | 10923 | 0.540 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 586 | 0.540 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 365 | 0.530 |
Why?
| | Infant | 21 | 2025 | 9574 | 0.530 |
Why?
| | Exome | 1 | 2018 | 235 | 0.520 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 695 | 0.520 |
Why?
| | Male | 46 | 2025 | 68260 | 0.500 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 99 | 0.500 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 525 | 0.490 |
Why?
| | Disease Management | 1 | 2020 | 622 | 0.490 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 334 | 0.480 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 335 | 0.470 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 819 | 0.460 |
Why?
| | Risk Factors | 15 | 2024 | 10252 | 0.460 |
Why?
| | Cardiology | 1 | 2017 | 279 | 0.450 |
Why?
| | Stroke | 1 | 2023 | 1136 | 0.440 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5112 | 0.430 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 155 | 0.420 |
Why?
| | Young Adult | 13 | 2024 | 13305 | 0.410 |
Why?
| | Myocardium | 3 | 2022 | 921 | 0.410 |
Why?
| | Benchmarking | 5 | 2024 | 187 | 0.410 |
Why?
| | Female | 35 | 2025 | 73763 | 0.390 |
Why?
| | Sequence Analysis, RNA | 2 | 2014 | 448 | 0.390 |
Why?
| | Consensus | 3 | 2025 | 685 | 0.360 |
Why?
| | Histones | 1 | 2017 | 632 | 0.360 |
Why?
| | Postoperative Complications | 6 | 2025 | 2722 | 0.350 |
Why?
| | Risk Assessment | 6 | 2023 | 3433 | 0.350 |
Why?
| | Echocardiography | 3 | 2022 | 640 | 0.340 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2590 | 0.330 |
Why?
| | Mutation | 2 | 2019 | 3987 | 0.330 |
Why?
| | Dietary Supplements | 3 | 2019 | 553 | 0.330 |
Why?
| | Delivery of Health Care | 1 | 2017 | 958 | 0.330 |
Why?
| | Metabolomics | 4 | 2024 | 689 | 0.320 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 98 | 0.320 |
Why?
| | Waiting Lists | 4 | 2024 | 241 | 0.310 |
Why?
| | Computational Biology | 4 | 2025 | 649 | 0.310 |
Why?
| | Cimicifuga | 2 | 2019 | 2 | 0.300 |
Why?
| | Plant Preparations | 2 | 2019 | 36 | 0.300 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 57 | 0.300 |
Why?
| | Transplant Recipients | 4 | 2024 | 173 | 0.300 |
Why?
| | Databases, Factual | 5 | 2024 | 1415 | 0.290 |
Why?
| | Everolimus | 2 | 2025 | 110 | 0.280 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 118 | 0.270 |
Why?
| | Genomics | 4 | 2023 | 796 | 0.260 |
Why?
| | Tacrolimus | 2 | 2025 | 192 | 0.260 |
Why?
| | Infant, Newborn | 11 | 2025 | 6144 | 0.260 |
Why?
| | Computer Simulation | 4 | 2021 | 996 | 0.250 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 502 | 0.250 |
Why?
| | Formaldehyde | 2 | 2018 | 67 | 0.250 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 488 | 0.250 |
Why?
| | DNA Damage | 3 | 2018 | 422 | 0.250 |
Why?
| | Plant Extracts | 2 | 2018 | 207 | 0.250 |
Why?
| | Survival Rate | 4 | 2025 | 1935 | 0.240 |
Why?
| | Incidence | 4 | 2025 | 2747 | 0.240 |
Why?
| | Stroke Volume | 4 | 2022 | 584 | 0.220 |
Why?
| | Interleukin-6 | 1 | 2009 | 785 | 0.220 |
Why?
| | Time Factors | 6 | 2025 | 6851 | 0.220 |
Why?
| | Alkanesulfonic Acids | 1 | 2025 | 41 | 0.220 |
Why?
| | Biotransformation | 1 | 2024 | 62 | 0.220 |
Why?
| | Aflatoxin B1 | 2 | 2014 | 2 | 0.220 |
Why?
| | Rats | 9 | 2024 | 5594 | 0.210 |
Why?
| | Kidney | 2 | 2023 | 1466 | 0.210 |
Why?
| | DNA | 2 | 2019 | 1438 | 0.210 |
Why?
| | Animal Testing Alternatives | 2 | 2021 | 3 | 0.210 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1482 | 0.210 |
Why?
| | Adverse Outcome Pathways | 1 | 2023 | 4 | 0.200 |
Why?
| | Animals | 21 | 2025 | 37217 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1229 | 0.200 |
Why?
| | Fluorocarbons | 1 | 2025 | 116 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2025 | 2049 | 0.200 |
Why?
| | Vasoplegia | 1 | 2022 | 5 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 40 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 119 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 148 | 0.190 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 35 | 0.190 |
Why?
| | Hep G2 Cells | 2 | 2025 | 67 | 0.190 |
Why?
| | American Heart Association | 2 | 2021 | 293 | 0.190 |
Why?
| | Rodentia | 1 | 2022 | 59 | 0.190 |
Why?
| | Ginkgo biloba | 2 | 2018 | 9 | 0.180 |
Why?
| | Organisation for Economic Co-Operation and Development | 1 | 2021 | 2 | 0.180 |
Why?
| | Hepatocytes | 2 | 2019 | 211 | 0.180 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 575 | 0.180 |
Why?
| | Adult | 11 | 2024 | 38201 | 0.180 |
Why?
| | Mutagenicity Tests | 2 | 2019 | 13 | 0.180 |
Why?
| | Databases, Chemical | 2 | 2019 | 9 | 0.170 |
Why?
| | Clinical Protocols | 1 | 2022 | 273 | 0.170 |
Why?
| | Pesticides | 1 | 2021 | 62 | 0.170 |
Why?
| | Coronary Vessels | 2 | 2021 | 247 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1323 | 0.160 |
Why?
| | Age Factors | 4 | 2021 | 3256 | 0.160 |
Why?
| | Echinacea | 1 | 2019 | 2 | 0.160 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.160 |
Why?
| | Quantitative Structure-Activity Relationship | 2 | 2017 | 19 | 0.160 |
Why?
| | Cohort Studies | 5 | 2024 | 5697 | 0.150 |
Why?
| | Stents | 1 | 2023 | 526 | 0.150 |
Why?
| | Arsenites | 1 | 2019 | 6 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.150 |
Why?
| | Logistic Models | 1 | 2024 | 2065 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 896 | 0.150 |
Why?
| | United States | 9 | 2022 | 14938 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 143 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 55 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 333 | 0.150 |
Why?
| | Food Contamination | 1 | 2018 | 55 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 102 | 0.150 |
Why?
| | Eugenol | 1 | 2018 | 4 | 0.150 |
Why?
| | Fontan Procedure | 1 | 2021 | 182 | 0.140 |
Why?
| | Ultrasonography | 2 | 2020 | 745 | 0.140 |
Why?
| | Biomarkers | 7 | 2018 | 4092 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2018 | 37 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2018 | 33 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 315 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 157 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2018 | 728 | 0.140 |
Why?
| | Prostate | 1 | 2019 | 173 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 262 | 0.140 |
Why?
| | Mice, Inbred Strains | 1 | 2018 | 411 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2021 | 295 | 0.130 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 364 | 0.130 |
Why?
| | Isoantibodies | 1 | 2017 | 54 | 0.130 |
Why?
| | Cryopreservation | 1 | 2018 | 104 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 676 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 383 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2844 | 0.130 |
Why?
| | Uniparental Disomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Donor Selection | 1 | 2017 | 74 | 0.130 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 22 | 0.130 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 30 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 113 | 0.130 |
Why?
| | Tooth Extraction | 1 | 2017 | 25 | 0.130 |
Why?
| | Arsenic | 1 | 2017 | 63 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 1488 | 0.130 |
Why?
| | Research Design | 2 | 2023 | 1118 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 112 | 0.130 |
Why?
| | DNA Repair | 2 | 2019 | 229 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 132 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3307 | 0.130 |
Why?
| | HLA Antigens | 1 | 2017 | 233 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2019 | 391 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1482 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 76 | 0.120 |
Why?
| | Systems Biology | 1 | 2016 | 70 | 0.120 |
Why?
| | Models, Chemical | 1 | 2017 | 270 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 277 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2017 | 117 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 135 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 517 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2018 | 761 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 528 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 129 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 578 | 0.120 |
Why?
| | Heme Oxygenase-1 | 1 | 2015 | 64 | 0.120 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 186 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 409 | 0.110 |
Why?
| | Aromatase Inhibitors | 1 | 2015 | 58 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 176 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2024 | 2815 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 213 | 0.110 |
Why?
| | Equipment Failure | 1 | 2015 | 110 | 0.110 |
Why?
| | Biomarkers, Pharmacological | 1 | 2014 | 26 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 88 | 0.110 |
Why?
| | Rats, Inbred F344 | 1 | 2014 | 267 | 0.110 |
Why?
| | Vaccination | 4 | 2024 | 1437 | 0.110 |
Why?
| | Cell Survival | 1 | 2017 | 1123 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 516 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 251 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 716 | 0.100 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 316 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2013 | 42 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 768 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 469 | 0.100 |
Why?
| | Hemodynamics | 2 | 2018 | 1093 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1102 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2749 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1213 | 0.100 |
Why?
| | Heart | 2 | 2022 | 611 | 0.090 |
Why?
| | Genetic Diseases, Inborn | 1 | 2012 | 45 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1072 | 0.090 |
Why?
| | Hospitalization | 1 | 2022 | 2235 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1096 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 590 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 326 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1032 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2015 | 403 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 858 | 0.080 |
Why?
| | Recovery of Function | 1 | 2015 | 665 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 659 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 298 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1316 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 39 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1078 | 0.080 |
Why?
| | Prognosis | 3 | 2018 | 3984 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 56 | 0.080 |
Why?
| | Signal Transduction | 3 | 2018 | 5086 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2030 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2480 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1941 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 433 | 0.080 |
Why?
| | Carcinogenicity Tests | 2 | 2022 | 10 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5803 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 520 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 320 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2017 | 1518 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 649 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 228 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 675 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1309 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 406 | 0.070 |
Why?
| | Biological Assay | 2 | 2018 | 130 | 0.070 |
Why?
| | RNA | 1 | 2014 | 925 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 16 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 76 | 0.070 |
Why?
| | Neoplasms | 1 | 2022 | 2681 | 0.070 |
Why?
| | Genotype | 2 | 2009 | 1842 | 0.060 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2019 | 56 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2499 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1047 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 23 | 0.060 |
Why?
| | Biopsy | 1 | 2009 | 1072 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 562 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 58 | 0.060 |
Why?
| | Exons | 2 | 2019 | 353 | 0.060 |
Why?
| | Caprylates | 1 | 2025 | 25 | 0.060 |
Why?
| | Aged | 2 | 2023 | 24024 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 623 | 0.050 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 107 | 0.050 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 113 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 309 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 195 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 164 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2490 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 7554 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 41 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 155 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2876 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 540 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1924 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 404 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 132 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.040 |
Why?
| | Bias | 1 | 2022 | 226 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 234 | 0.040 |
Why?
| | Data Accuracy | 1 | 2021 | 65 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 286 | 0.040 |
Why?
| | Middle Aged | 2 | 2021 | 33604 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 196 | 0.040 |
Why?
| | Social Class | 1 | 2022 | 266 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 215 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4181 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 278 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5520 | 0.040 |
Why?
| | PPAR alpha | 1 | 2019 | 57 | 0.040 |
Why?
| | Carcinogens, Environmental | 1 | 2019 | 14 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 198 | 0.040 |
Why?
| | Cricetulus | 1 | 2019 | 110 | 0.040 |
Why?
| | CHO Cells | 1 | 2019 | 167 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Chickens | 1 | 2019 | 189 | 0.040 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 44 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2018 | 7 | 0.040 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2018 | 7 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 31 | 0.040 |
Why?
| | Anemia, Megaloblastic | 1 | 2018 | 9 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 197 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 176 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2019 | 303 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 41 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 208 | 0.030 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 3 | 0.030 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 6 | 0.030 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 6 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2021 | 734 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 245 | 0.030 |
Why?
| | Activation, Metabolic | 1 | 2017 | 5 | 0.030 |
Why?
| | Barth Syndrome | 1 | 2017 | 8 | 0.030 |
Why?
| | Phytotherapy | 1 | 2018 | 81 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2019 | 243 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 202 | 0.030 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 10 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 80 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 195 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 166 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 39 | 0.030 |
Why?
| | Infliximab | 1 | 2017 | 111 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2016 | 17 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 184 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 67 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 147 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 127 | 0.030 |
Why?
| | Death | 1 | 2017 | 125 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 241 | 0.030 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 41 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 629 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 319 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 74 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 78 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 55 | 0.030 |
Why?
| | Canada | 1 | 2017 | 407 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 126 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 355 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1656 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1224 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 565 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 122 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 74 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 243 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1949 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 17 | 0.030 |
Why?
| | Kidney Tubules, Proximal | 1 | 2015 | 132 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 395 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.030 |
Why?
| | Gene Library | 1 | 2014 | 118 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 346 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3523 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 319 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 310 | 0.030 |
Why?
| | Electrocardiography | 1 | 2017 | 612 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1192 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 2013 | 17 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1233 | 0.030 |
Why?
| | E2F1 Transcription Factor | 1 | 2013 | 64 | 0.020 |
Why?
| | Radiation Effects | 1 | 2012 | 7 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 986 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 193 | 0.020 |
Why?
| | Erythrocytes | 1 | 2018 | 701 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 227 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 994 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1587 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 525 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2013 | 165 | 0.020 |
Why?
| | Testosterone | 1 | 2015 | 402 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 166 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3392 | 0.020 |
Why?
| | Tobacco Products | 1 | 2012 | 129 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2851 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2954 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 746 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 335 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1157 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4106 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1388 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 119 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 112 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 571 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 508 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 494 | 0.020 |
Why?
| | Subclavian Vein | 1 | 2006 | 15 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 6829 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 887 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2174 | 0.010 |
Why?
| | Mice | 1 | 2018 | 17814 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3139 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|